Sign In
Buy GERN
$1.16
-0.0100 (-0.85%)
At Close: Jun 03, 2026
Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors
07:01am, Thursday, 07'th Nov 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced up t
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 17'th Oct 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggr
Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024
04:30pm, Tuesday, 15'th Oct 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its third quarter 2024 financial results and
Geron: Derisked And Highly Attractive After Approval
05:17pm, Monday, 23'rd Sep 2024
Geron's imetelstat (Rytelo) received FDA approval for MDS, marking a significant milestone despite past setbacks and negative comments from the FDA. Imetelstat, a telomerase inhibitor, shows promise i
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 19'th Sep 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggr
Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer
04:15pm, Monday, 09'th Sep 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, announced the appoin
Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
09:17am, Thursday, 08'th Aug 2024
Geron (GERN) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.09 per share a year ago.
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that
Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024
04:30pm, Thursday, 18'th Jul 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and
3 Under-$10 Biotech Stocks That Could Make You Rich
02:23pm, Thursday, 11'th Jul 2024
Low-cap biotech companies are a high-risk but high-reward investment choice. If their clinical trials are successful, that can often mean an explosion in value as investors anticipate a buyout.
3 Longevity Stocks to Buy for Anti-Aging Breakthroughs
07:09pm, Monday, 08'th Jul 2024
The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago.
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 20'th Jun 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggr
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
10:00am, Tuesday, 11'th Jun 2024
Investing in penny stocks can be a thrilling way to explore the potential for substantial gains. Despite their inherent risks, these stocks often appeal to adventurous investors looking to diversify t
Geron (GERN) Wins FDA Approval for Blood Cancer Drug, Stock Up
01:01pm, Monday, 10'th Jun 2024
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
Is Geron Stock a Buy Following Its First New Drug Approval?
06:37am, Saturday, 08'th Jun 2024
The U.S. Food and Drug Administration approved Geron's lead candidate on June 6, under the brand name Rytelo. Peak Rytelo sales could surpass $1 billion annually.
